A patent and literature review of CDK12 inhibitors

References

• Satyanarayana A, Kaldis P. Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene. 2009 [2009 August 01];28(33):2925–2939.
   PubMed Web of Science ®Google Scholar
• Bartkowiak B, Liu PD, Phatnani HP, et al. CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1. Genes Dev. 2010 Oct 15 24(20):2303–2316.
   PubMed Web of Science ®Google Scholar
• Cheng SWG, Kuzyk MA, Moradian A, et al. Interaction of cyclin-dependent kinase 12/CrkRS with cyclin K1 is required for the phosphorylation of the C-terminal domain of RNA polymerase II. Mol Cell Biol. 2012 Nov;32(22):4691–4704.
   PubMed Web of Science ®Google Scholar
• Bosken CA, Farnung L, Hintermair C, et al. The structure and substrate specificity of human Cdk12/Cyclin K. Nat Commun. 2014 Mar 5;5: DOI:10.1038/ncomms4505
   PubMed Web of Science ®Google Scholar
• Blazek D, Kohoutek J, Bartholomeeusen K, et al. The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. Genes Dev. 2011 Oct 15 25(20):2158–2172.
   PubMed Web of Science ®Google Scholar
• Manavalan APC, Pilarova K, Kluge M, et al. CDK12 controls G1/S progression by regulating RNAPII processivity at core DNA replication genes. EMBO Rep. 2019 Sep;20(9):e47592.
   PubMed Web of Science ®Google Scholar
• Dubbury SJ, Boutz PL, Sharp PA. CDK12 regulates DNA repair genes by suppressing intronic polyadenylation. Nature. 2018 Dec 6; 564(7734):141–145.
   PubMed Web of Science ®Google Scholar
• Krajewska M, Dries R, Grassetti AV, et al. CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation. Nat Commun. 2019 Apr 15; 10;10: DOI:10.1038/s41467-019-09703-y
   PubMed Web of Science ®Google Scholar
• Choi SH, Martinez TF, Kim S, et al. CDK12 phosphorylates 4E-BP1 to enable mTORC1-dependent translation and mitotic genome stability. Genes Dev. 2019 Apr 1 33(7–8):418–435.
   PubMed Web of Science ®Google Scholar
• Tien JF, Mazloomian A, Cheng S-WG, et al. CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion. Nucleic Acids Res. 2017 Jun 20 45(11):6698–6716.
   PubMed Web of Science ®Google Scholar
• Naidoo K, Wai PT, Maguire SL, et al. Evaluation of CDK12 protein expression as a potential novel biomarker for DNA damage response-targeted therapies in breast cancer. Mol Cancer Ther. 2018 Jan;17(1):306–315.
   PubMed Web of Science ®Google Scholar
• Ekumi KM, Paculova H, Lenasi T, et al. Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12/CycK complex. Nucleic Acids Res. 2015 Mar 11 43(5):2575–2589.
   PubMed Web of Science ®Google Scholar
• Wu YM, Cieslik M, Lonigro RJ, et al. Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer. Cell. 2018 Jun 14 173(7):1770–+.
   PubMed Web of Science ®Google Scholar
• Schweizer MT, Ha G, Gulati R, et al. CDK12-mutated prostate cancer: clinical outcomes with standard therapies and immune checkpoint blockade. JCO Precis Oncol. 2020;4:382–392.
   PubMed Web of Science ®Google Scholar
• Lui GYL, Grandori C, Kemp CJ. CDK12: an emerging therapeutic target for cancer. J Clin Pathol. 2018 Nov;71(11):957–962.
   PubMed Web of Science ®Google Scholar
• Paculova H, Kohoutek J. The emerging roles of CDK12 in tumorigenesis. Cell Div. 2017;12:7.
   PubMed Web of Science ®Google Scholar
• Liu H, Liu K, Dong Z. Targeting CDK12 for cancer therapy: function, mechanism, and drug discovery. Cancer Res. 2021 Jan 1;81(1):18–26.
   PubMed Web of Science ®Google Scholar
• Pilarova K, Herudek J, Blazek D. CDK12: cellular functions and therapeutic potential of versatile player in cancer. NAR Cancer. 2020;2(1). DOI:10.1093/narcan/zcaa003
   PubMedGoogle Scholar
• Liang S, Hu L, Wu Z, et al. CDK12: a potent target and biomarker for human cancer therapy. Cells. 2020 Jun 18 9(6):1483.
   Web of Science ®Google Scholar
• Emadi F, Teo T, Rahaman MH, et al. CDK12: a potential therapeutic target in cancer. Drug Discov Today. 2020 Dec;25(12):2257–2267.
   PubMed Web of Science ®Google Scholar
• Choi HJ, Jin S, Cho H, et al. CDK12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS1-ErbB-PI3K signaling. EMBO Rep. 2019 Oct 4;20(10). DOI:10.15252/embr.201948058.
   Web of Science ®Google Scholar
• Toyoshima M, Howie HL, Imakura M, et al. Functional genomics identifies therapeutic targets for MYC-driven cancer. Proc Natl Acad Sci U S A. 2012 Jun 12 109(24):9545–9550.
   PubMed Web of Science ®Google Scholar
• Iniguez AB, Stolte B, Wang EJ, et al. EWS/FLI confers tumor cell synthetic lethality to CDK12 inhibition in Ewing sarcoma. Cancer Cell. 2018 Feb 12 33(2):202–+.
   PubMed Web of Science ®Google Scholar
• Paculova H, Kramara J, Simeckova S, et al. BRCA1 or CDK12 loss sensitizes cells to CHK1 inhibitors. Tumour Biol. 2017 Oct;39(10):1010428317727479.
   Google Scholar
• Johnson SF, Cruz C, Greifenberg AK, et al. CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer. Cell Rep. 2016 Nov 22 17(9):2367–2381.
   PubMed Web of Science ®Google Scholar
• Bajrami I, Frankum JR, Konde A, et al. Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity. Cancer Res. 2014 Jan 1 74(1):287–297.
   PubMed Web of Science ®Google Scholar
• Ketley A, Wojciechowska M, Ghidelli-Disse S, et al. CDK12 inhibition reduces abnormalities in cells from patients with myotonic dystrophy and in a mouse model. Sci Transl Med. 2020 Apr 29;12(541). DOI:10.1126/scitranslmed.aaz2415.
   PubMed Web of Science ®Google Scholar
• Tadesse S, Duckett DR, Monastyrskyi A. The promise and current status of CDK12/13 inhibition for the treatment of cancer. Future Med Chem. 2021 Jan;13(2):117–141.
   PubMed Web of Science ®Google Scholar
• Johannes JW, Denz CR, Su N, et al. Structure-Based design of selective noncovalent CDK12 inhibitors. ChemMedChem. 2018 Feb 6 13(3):231–235.
   PubMed Web of Science ®Google Scholar
• The scripps research institute, assignee. Small Molecule Inhibitors of CDK12/CDK13 patent WO217421A1. 2019.
   Google Scholar
• Quereda V, Bayle S, Vena F, et al. Therapeutic Targeting of CDK12/CDK13 in triple-negative breast cancer. Cancer Cell. 2019 Nov 11 36(5):545–558 e7.
   PubMed Web of Science ®Google Scholar
• Aurigene discovery technologies limited, assignee. Substituted pyrazole derivatives as selective CDK12/13 inhibitors patent WO193529A1. 2019.
   Google Scholar
• Ito M, Tanaka T, Toita A, et al. Discovery of 3 Benzyl-1-(trans −4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea derivatives as novel and selective Cyclin-dependent kinase 12 (CDK12) inhibitors. J Med Chem. 2018 Sep 13 61(17):7710–7728.
   PubMed Web of Science ®Google Scholar
• The University of Nottingham, assignee. Inhibitors and their uses patent WO163076Al. 2017.
   Google Scholar
• De Vita E. 10 years into the resurgence of covalent drugs. Future Med Chem. 2021 Jan;13(2):193–210.
   PubMed Web of Science ®Google Scholar
• Bandyopadhyay A, Gao J. Targeting biomolecules with reversible covalent chemistry. Curr Opin Chem Biol. 2016 Oct;34:110–116.
   PubMed Web of Science ®Google Scholar
• Sutanto F, Konstantinidou M, Domling A. Covalent inhibitors: a rational approach to drug discovery. RSC Med Chem. 2020 Aug 1;11(8):876–884.
   PubMedGoogle Scholar
• Zhang T, Kwiatkowski N, Olson CM, et al. Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nat Chem Biol. 2016 Oct;12(10):876–884.
   PubMed Web of Science ®Google Scholar
• Patricelli MP, Nomanbhoy TK, Wu J, et al. In situ kinase profiling reveals functionally relevant properties of native kinases. Chem Biol. 2011 Jun 24 18(6):699–710.
   PubMedGoogle Scholar
• Dana-Farber Cancer Institute, assignee. Inhibitors of Cyclin-dependent kinase 12 (CDK12) and uses thereof patent WO098361Al. 2018.
   Google Scholar
• Jiang B, Jiang J, Kaltheuner IH, et al. Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing sarcoma. Eur J Med Chem. 2021 [2021 October 05];221:113481.
   PubMed Web of Science ®Google Scholar
• Dana-Farber Cancer Institute, assignee. Inhibitors of cyclin-dependent kinases patent WO160617A2. 2016.
   Google Scholar
• Gao Y, Zhang T, Terai H, et al. Overcoming resistance to the THZ series of covalent transcriptional CDK inhibitors. Cell Chem Biol. 2018 Feb 15 25(2):135–142 e5.
   PubMed Web of Science ®Google Scholar
• Dana-Farber Cancer Institute, assignee. Inhibitors of cyclin-dependent kinases patent WO044858A2. 2017.
   Google Scholar
• Liu Y, Hao M, Leggett AL, et al.Discovery of MFH290: a potent and highly selective covalent inhibitor for cyclin-dependent kinase 12/13. J Med Chem. 2020 Jul 9 63(13):6708–6726.
   PubMed Web of Science ®Google Scholar
• The University of Nottingham, assignee.Heterocyclyl substituted pyrrolopyridines that are inhibitors of the CDK12 kinase patent WO058132Al. 2019.
   Google Scholar
• Kinnate Biopharma INC assignee. Inhibitors of cyclin-dependent kinases patent WO006497A1. 2020.
   Google Scholar
• Aurigene Discovery Technologies Limited, assignee. Substituted 5-cyclopropyl-1H-pyrazol-3-yl-amine derivatives as selective CDK12/13 inhibitors patent WO202001A1. 2020.
   Google Scholar
• Schneider M, Radoux CJ, Hercules A, et al. The PROTACtable genome. Nat Rev Drug Discov. 2021 Oct; 20(10):789–797.
   PubMed Web of Science ®Google Scholar
• Sakamoto KM, Kim KB, Kumagai A, et al. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc Natl Acad Sci U S A. 2001 Jul 17 98(15):8554–8559.
   PubMed Web of Science ®Google Scholar
• Olson CM, Jiang B, Erb MA, et al. Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. Nat Chem Biol. 2018 Feb;14(2):163–170.
   PubMed Web of Science ®Google Scholar
• Rana S, Bendjennat M, Kour S, et al. Selective degradation of CDK6 by a palbociclib based PROTAC. Bioorg Med Chem Lett. 2019 Jun 1 29(11):1375–1379.
   PubMed Web of Science ®Google Scholar
• Wang L, Shao X, Zhong T, et al. Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy. Nat Chem Biol. 2021 May;17(5):567–575.
   PubMed Web of Science ®Google Scholar
• Dana-Farber cancer institute, assignee. Degraders of cyclin dependent kinases (CDK12) and use thereof patent WO219650A1. 2020.
   Google Scholar
• Jiang B, Gao Y, Che J, et al. Discovery and resistance mechanism of a selective CDK12 degrader. Nat Chem Biol. 2021 [2021 June 1];17(6):675–683.
   PubMed Web of Science ®Google Scholar
• Niu T, Li K, Jiang L, et al. Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor. Eur J Med Chem. 2022 Jan 15;228:114012.
   PubMed Web of Science ®Google Scholar
• Stanton BZ, Chory EJ, Crabtree GR. Chemically induced proximity in biology and medicine. Science. 2018 Mar 9;3596380. 10.1126/science.aao5902
   PubMed Web of Science ®Google Scholar
• Slabicki M, Kozicka Z, Petzold G, et al. The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K. Nature. 2020 Sep 10 585(7824):293–+.
   PubMed Web of Science ®Google Scholar
• Mayor-Ruiz C, Bauer S, Brand M, et al. Rational discovery of molecular glue degraders via scalable chemical profiling. Nat Chem Biol. 2020 Nov;16(11):1199–1207.
   PubMed Web of Science ®Google Scholar
• Lv L, Chen PH, Cao LZ, et al. Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation. Elife. 2020 Aug 17;9: DOI:10.7554/eLife.59994
   PubMed Web of Science ®Google Scholar
• Bayer Aktiengeellschaft and Deutsches Krebsforschungszentrum, assignee. Pyrazolotriazines patent WO116178A1. 2021.
   Google Scholar
• Bayer Aktiengesellschaft and Deutsches Krebsforschungszentrum, assignee. Imidazotriazines acting on cancer via inhibition of CDK12 patent WO176045A1. 2021.
   Google Scholar
• Bayer Aktiengesellschaft and Deutsches Krebsforschungszentrum, assignee. Pyrazolopyrazines acting on cancers via inhibition of CDK12 patent WO176049A1. 2021.
   Google Scholar
• Pan ZQ, Kentsis A, Dias DC, et al. Nedd8 on cullin: building an expressway to protein destruction. Oncogene. 2004 Mar 15 23(11):1985–1997.
   PubMed Web of Science ®Google Scholar
• Lv L, Chen P, Cao L, et al.Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger Cyclin K degradation. Elife. 2020 Aug 17; 9:e59994.
   PubMed Web of Science ®Google Scholar